ERJ Open ResearchPub Date : 2025-01-20eCollection Date: 2025-01-01DOI: 10.1183/23120541.50791-2023
{"title":"Erratum: \"Patients at risk of nontuberculous mycobacterial pulmonary disease who need testing evaluated using a modified Delphi process by European experts.\" Michael R. Loebinger, Stefano Aliberti, Charles Haworth, Mateja Jankovic Makek, Christoph Lange, Natalie Lorent, Apostolos Papavasileiou, Eva Polverino, Gernot Rohde, Nicolas Veziris, Dirk Wagner and Jakko van Ingen. <i>ERJ Open Res</i> 2024; 10: 00791-2023.","authors":"","doi":"10.1183/23120541.50791-2023","DOIUrl":"https://doi.org/10.1183/23120541.50791-2023","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1183/23120541.00791-2023.].</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How to distinguish PPI-refractory from PPI-responsive patients in gastro-oesophageal reflux-induced chronic cough: post-reflux swallow induced peristaltic wave index and mean nocturnal baseline impedance provide new predictive factors.","authors":"Wanzhen Li, Bingxian Sha, Haodong Bai, Tongyangzi Zhang, Shengyuan Wang, Yadav Ambedkar Kumar, Yiqing Zhu, Li Yu, Xianghuai Xu","doi":"10.1183/23120541.00299-2024","DOIUrl":"10.1183/23120541.00299-2024","url":null,"abstract":"<p><strong>Background: </strong>The results of empirical trials with proton pump inhibitors (PPIs) for management of gastro-oesophageal reflux-induced chronic cough (GERC) have resulted in considerable controversy, and the mechanism of PPI refractoriness remains unclear. Our study aims to identify the predictors of PPI refractoriness of GERC in a retrospective clinical study.</p><p><strong>Methods: </strong>In total, 128 GERC patients were enrolled between March 2018 and October 2022. Regression analysis was utilised to create a model for predicting PPI-refractory of GERC using retrospective analysis of the general data and MII-pH indicators.</p><p><strong>Results: </strong>The post-reflux swallow induced peristaltic wave index (PSPWI) was lower in the PPI-refractory group than the PPI-responsive group (33.89±7.38 <i>versus</i> 39.45±9.47, respectively, p<0.001), as were the mean nocturnal baseline impedance (MNBI) and proximal MNBI (2092.11 (IQR: 652.23)] <i>versus</i> 2426.52 (IQR: 917.39) Ω, respectively, p=0.012; 1599.50 (IQR: 1206.63) <i>versus</i> 2274.50 (IQR: 1775.29) Ω, respectively, p=0.001). Multivariate logistic regression analysis identified the PSPWI (odds ratio 0.919, p=0.001) as an independent predictor of PPI-refractory GERC.</p><p><strong>Conclusions: </strong>The diagnostic value of both proximal MNBI ≤39.90% and MNBI ≤2233.58 Ω had moderate sensitivity (71.67%) and specificity (75.00%) to identify PPI-refractory GERC.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ERJ Open ResearchPub Date : 2025-01-20eCollection Date: 2025-01-01DOI: 10.1183/23120541.00395-2024
Kristoffer Mazanti Cold, Kaladerhan Agbontaen, Anne Orholm Nielsen, Christian Skjoldvang Andersen, Suveer Singh, Lars Konge
{"title":"Artificial intelligence improves bronchoscopy performance: a randomised crossover trial.","authors":"Kristoffer Mazanti Cold, Kaladerhan Agbontaen, Anne Orholm Nielsen, Christian Skjoldvang Andersen, Suveer Singh, Lars Konge","doi":"10.1183/23120541.00395-2024","DOIUrl":"10.1183/23120541.00395-2024","url":null,"abstract":"<p><strong>Rationale: </strong>Flexible bronchoscopy is an operator-dependent procedure. An automatic bronchial identification system based on artificial intelligence (AI) could help bronchoscopists to perform more complete and structured procedures through automatic guidance.</p><p><strong>Methods: </strong>101 participants were included from six different continents at the European Respiratory Society annual conference in Milan, 9-13 September 2023. Participants were split into three groups based on experience: novices (0 bronchoscopies), intermediates (1-249 bronchoscopies) and experienced (≥250 bronchoscopies). The participants performed two bronchoscopies on a realistic physical phantom, one with AI (AmbuBronchoSimulatorTrainingGUIDEv.0.0.1, Prototype version, Ambu) and one Standard procedure. The F1-group received AI guidance for their first procedure, the F2-group for their second. A crossover randomisation controlled for learning by testing. All procedures were automatically rated according to the outcome measures: inspected segments, structured progressions and procedure time.</p><p><strong>Results: </strong>AI guidance caused the participants to inspect more segments (mean difference, paired t-test: +6.0 segments, p<0.001), perform more structured progressions (+5.2 progressions, p<0.001) and spend more time on the procedure (+72 s, p<0.001) compared to their standard procedures. The effects of AI guidance on inspected segments and structured progression were highest for novices but significant for all experience groups: novices (+8.2 segments, p=0.012 and +6.6 progressions, p<0.001), intermediates (+5.7 segments, p=0.006 and +5.1 progressions, p<0.001) and experienced (+4.3 segments, p=0.006 and +3.8 progressions, p<0.016).</p><p><strong>Conclusions: </strong>AI guidance helped bronchoscopists of all experience levels to inspect more segments in a more structured order. Clinical implementation of AI guidance could help ensure and document more complete bronchoscopy procedures in the future.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ERJ Open ResearchPub Date : 2025-01-20eCollection Date: 2025-01-01DOI: 10.1183/23120541.00794-2024
Shuxin Zhong, Ruchong Chen, Huda Badri
{"title":"Gastro-oesophageal reflux-related chronic cough: can new tools improve patient assessment?","authors":"Shuxin Zhong, Ruchong Chen, Huda Badri","doi":"10.1183/23120541.00794-2024","DOIUrl":"10.1183/23120541.00794-2024","url":null,"abstract":"<p><p><b>Novel impedance pH monitoring parameters, such as mean nocturnal baseline impedance and post-reflux swallow induced peristaltic wave index, may be better markers for assessing chronic cough related to oesophageal hypersensitivity</b> https://bit.ly/41woxTD.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ERJ Open ResearchPub Date : 2025-01-20eCollection Date: 2025-01-01DOI: 10.1183/23120541.00767-2024
Roman F Kind, Michael Furian, Aline Buergin, Philipp M Scheiwiller, Laura Mayer, Simon R Schneider, Mona Lichtblau, Lara Muralt, Maamed Mademilov, Talant M Sooronbaev, Silvia Ulrich, Konrad E Bloch
{"title":"Effects of acetazolamide on exercise performance in patients with COPD going to high altitude: randomised controlled trial.","authors":"Roman F Kind, Michael Furian, Aline Buergin, Philipp M Scheiwiller, Laura Mayer, Simon R Schneider, Mona Lichtblau, Lara Muralt, Maamed Mademilov, Talant M Sooronbaev, Silvia Ulrich, Konrad E Bloch","doi":"10.1183/23120541.00767-2024","DOIUrl":"10.1183/23120541.00767-2024","url":null,"abstract":"<p><strong>Background: </strong>In patients with COPD, preventive treatment with acetazolamide reduces adverse health effects during altitude travel. We investigated whether preventive acetazolamide treatment modifies exercise performance in COPD patients going to high altitude.</p><p><strong>Methods: </strong>In this randomised, double-blind trial, lowlanders with COPD, forced expiratory volume in 1 s (FEV<sub>1</sub>) 40-80% predicted, were assigned to acetazolamide (375 mg per 24 h) or placebo treatment starting 24 h before ascent and while staying at 3100 m. Patients performed progressive cycling exercise to exhaustion at 760 m, before taking the study drug, and within 4 h after arrival at 3100 m. The primary outcome was the maximal power output (W<sub>max</sub>).</p><p><strong>Results: </strong>103 patients (32 women), mean±sd age 57.2±8.1 years, FEV<sub>1</sub> 66±11% predicted, were included in per-protocol analyses. In 53 patients receiving acetazolamide, W<sub>max</sub> and oxygen uptake (<i>V</i>'<sub>O<sub>2</sub></sub> <sub>max</sub>) at 760 m and 3100 m were 105±27 and 91±25 W, and 18.0±4.8 and 15.5±3.7 mL·min<sup>-1</sup>·kg<sup>-1</sup> (p<0.001, both changes). Corresponding W<sub>max</sub> and <i>V</i>'<sub>O<sub>2</sub></sub> <sub>max</sub> in 50 patients receiving placebo were 107±34 and 97±28 W, and 18.9±6.0 and 17.2±5.0 mL·min<sup>-1</sup>·kg<sup>-1</sup> (p<0.001, both changes). Between-group differences (95% CI) in altitude-induced W<sub>max</sub> changes were -3.0 W (-8.7 to +2.7, p=0.305) and in <i>V</i>'<sub>O<sub>2</sub></sub> <sub>max</sub> changes were -0.8 mL·min<sup>-1</sup>·kg<sup>-1</sup> (-2.1 to +0.5, p=0.213). Acetazolamide mitigated the altitude-induced reduction of <i>P</i> <sub>aO<sub>2</sub></sub> by 0.7 kPa (0.1 to 1.3, p=0.016). At 3100 m, maximal work rate with respiratory exchange ratio ≤1 was greater with acetazolamide than with placebo by 10.1 W (4.0 to 16.2, p=0.022).</p><p><strong>Conclusions: </strong>In lowlanders with COPD, preventive treatment with acetazolamide did not modify the altitude-induced reduction in maximal work rate. However, acetazolamide enhanced arterial oxygenation and submaximal, moderate-intensity work capacity compared with placebo.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ERJ Open ResearchPub Date : 2025-01-20eCollection Date: 2025-01-01DOI: 10.1183/23120541.00543-2024
Efpraxia Kritikaki, Gerasimos Terzis, Meera Soundararajan, Ioannis Vogiatzis, Davina C M Simoes
{"title":"Role of pulmonary rehabilitation in extracellular matrix protein expression in vastus lateralis muscle in atrophic and nonatrophic patients with COPD.","authors":"Efpraxia Kritikaki, Gerasimos Terzis, Meera Soundararajan, Ioannis Vogiatzis, Davina C M Simoes","doi":"10.1183/23120541.00543-2024","DOIUrl":"https://doi.org/10.1183/23120541.00543-2024","url":null,"abstract":"<p><strong>Background: </strong>In response to exercise-based pulmonary rehabilitation (PR), the type of muscle fibre remodelling differs between COPD patients with peripheral muscle wasting (atrophic patients with COPD) and those without wasting (nonatrophic patients with COPD). Extracellular matrix (ECM) proteins are major constituents of the cell micro-environment steering cell behaviour and regeneration. We investigated whether the composition of ECM in atrophic compared to nonatrophic patients with COPD differs in response to PR.</p><p><strong>Methods: </strong>Vastus lateralis muscle biopsies from 29 male COPD patients (mean±sem forced expiratory volume in 1 s: 43±6% predicted) classified according to their fat-free mass index as atrophic (<17 kg·m<sup>-2</sup>, n=10) or nonatrophic (≥17 kg·m<sup>-2</sup>, n=19) were analysed before and after a 10-week PR programme for myofibre distribution and size, whereas a selection of ECM molecules was quantified using ELISA and real-time PCR.</p><p><strong>Results: </strong>In nonatrophic patients with COPD PR was associated with increased myofibre type I distribution (by 6.6±2.3%) and cross-sectional area (CSA) (by 16.4±4.8%), whereas in atrophic patients with COPD, PR induced increased myofibre type IIa distribution (by 9.6±2.8%) and CSA (by 12.1±3.2%). PR induced diverse intramuscular ECM adaptations in atrophic compared to nonatrophic patients with COPD. Accordingly, following PR there was a significant increase in protein levels of ECM biomarkers (collagen type I by 90 pg·mL<sup>-1</sup>; collagen type IV by 120 pg·mL<sup>-1</sup>; decorin by 70 pg·mL<sup>-1</sup>) only in nonatrophic patients with COPD. Conversely, post-PR, osteopontin, a protein known for its dystrophic effects, and tenacin C, a necroptosis compensatory factor facilitating muscle regeneration, were upregulated at protein levels (by 280 pg·mL<sup>-1</sup>and 40 pg·mL<sup>-1</sup>, respectively) in atrophic patients with COPD, whereas fibronectin protein levels were decreased.</p><p><strong>Conclusions: </strong>These findings suggest that the differential PR-induced myofibre adaptations in atrophic compared to nonatrophic patients with COPD could be associated with inadequate remodelling of the intramuscular ECM environment.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ERJ Open ResearchPub Date : 2025-01-20eCollection Date: 2025-01-01DOI: 10.1183/23120541.00931-2024
Vishisht Mehta
{"title":"Artificial intelligence augmentation raises questions about the future of bronchoscopy.","authors":"Vishisht Mehta","doi":"10.1183/23120541.00931-2024","DOIUrl":"10.1183/23120541.00931-2024","url":null,"abstract":"<p><p><b>This editorial discusses the article by Cold<i>et al.</i> demonstrating improvements in bronchoscopy on a model when aided by artificial intelligence (AI) software. It explores hypothetical benefits and concerns stemming from AI-enhanced bronchoscopy.</b> https://bit.ly/3BAExJs.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association between impaired diffusion capacity and small airway dysfunction: a cross-sectional study.","authors":"Kunning Zhou, Fan Wu, Lifei Lu, Gaoying Tang, Zhishan Deng, Cuiqiong Dai, Ningning Zhao, Qi Wan, Jieqi Peng, Xiaohui Wu, Xianliang Zeng, Jiangyu Cui, Changli Yang, Shengtang Chen, Yongqing Huang, Shuqing Yu, Yumin Zhou, Pixin Ran","doi":"10.1183/23120541.00910-2023","DOIUrl":"10.1183/23120541.00910-2023","url":null,"abstract":"<p><strong>Background: </strong>Small airway dysfunction (SAD) and impaired diffusion capacity of the lungs for carbon monoxide (<i>D</i> <sub>LCO</sub>) are positively associated with a worse prognosis. Individuals with both dysfunctions have been identified in clinical practice and it is unknown whether they have worse health status or need management. We conducted this study to explore the association between SAD and impaired <i>D</i> <sub>LCO</sub>, and the difference between the groups with two dysfunctions, with either one dysfunction and with no dysfunction.</p><p><strong>Methods: </strong>This study involved subjects partly from those who had returned for the third-year follow-up (up to December 2022) of the Early Chronic Obstructive Pulmonary Disease study and those who newly participated. We assessed diffusion capacity, questionnaire, exacerbations, spirometry, impulse oscillometry (IOS) and computed tomography (CT). Impaired <i>D</i> <sub>LCO</sub> was defined as <i>D</i> <sub>LCO</sub> <80% predicted. Spirometry-defined SAD was defined using the percent predicted values of maximal mid-expiratory flow, and forced expiratory flow at 50% and 75% of forced vital capacity, at least two of these three values being <65% predicted after the use of a bronchodilator. IOS-defined SAD was defined when the difference in resistance at 5 and 20 Hz was >0.07 kPa·L<sup>-1</sup>·s. CT-defined SAD was defined when the percentage of expiratory low-attenuation areas <-856 HU comprised ≥15% of the total lung volume. Covariate analyses and logistic regression were performed to assess the association between impaired <i>D</i> <sub>LCO</sub> and SAD.</p><p><strong>Results: </strong>This study involved 581 subjects. The occurrence of both spirometry- and CT-defined SAD was significantly higher in subjects with impaired <i>D</i> <sub>LCO</sub> than normal <i>D</i> <sub>LCO</sub>. Subjects with two dysfunctions were associated with worse preceding year's exacerbations than controls.</p><p><strong>Conclusions: </strong>Impaired diffusion capacity is positively associated with SAD. Subjects with impaired diffusion capacity and SAD may have a worse health status and need additional management.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ERJ Open ResearchPub Date : 2025-01-13eCollection Date: 2025-01-01DOI: 10.1183/23120541.00221-2024
Fulvio Braido, Maria Giulia Candeliere, Benedetta Bondi, Enrico Arnaboldi, Matteo Bruno, Nicole Colombo, Cesare de Tommaso, Omar Fassio, Melissa Ferraris, Sofia Martinelli, Laura Melissari, Ludovica Napoli, Federica Terracciano, Chiara Folli, Ilaria Baiardini
{"title":"Chronic Cough Patient Perspective: questionnaire validation and symptom impact.","authors":"Fulvio Braido, Maria Giulia Candeliere, Benedetta Bondi, Enrico Arnaboldi, Matteo Bruno, Nicole Colombo, Cesare de Tommaso, Omar Fassio, Melissa Ferraris, Sofia Martinelli, Laura Melissari, Ludovica Napoli, Federica Terracciano, Chiara Folli, Ilaria Baiardini","doi":"10.1183/23120541.00221-2024","DOIUrl":"10.1183/23120541.00221-2024","url":null,"abstract":"<p><strong>Background: </strong>Chronic cough (CC) is underevaluated and underreported. The introduction of a tool that is easy to complete, score and interpret and with the psychometric properties requested for use in individual patients could improve clinical practice.</p><p><strong>Objective: </strong>This cross-sectional study aimed to validate the Chronic Cough Patient Perspective (CCPP) for assessing CC in daily practice.</p><p><strong>Methods: </strong>A provisional CCPP was created by iteratively reducing the Chronic Cough Impact Questionnaire (CCIQ). Its psychometric properties were tested in CC patients at baseline (visit 1) and after 1 month (visit 2).</p><p><strong>Results: </strong>The reduction process yielded an 8-item provisional version, subsequently validated in 150 patients (36.33% males, mean age 50±16.9 years). Exploratory factor analysis revealed a one-dimensional structure, with one item being deleted as it did not align with the extracted dimension. The 7-item version of the CCPP showed a strong correlation with the CCIQ (r=0.902 at visit 1, r=0.932 at visit 2) and internal consistency (Cronbach's alpha values: 0.85 at visit 1, 0.93 at visit 2); discriminant and convergent validity were satisfactory. The reliability, assessed in 21 patients with no change in CC (Global Rating Scale=0), was high (concordance correlation coefficient=0.815; interclass coefficient=0.823). A score ≤5 indicates optimal health-related quality of life (HRQoL) attainment, with a minimum important difference of 3. The mean CCPP score was 20.5±6.24 at enrolment, and only 37.33% of the participants achieved an optimal HRQoL at visit 2.</p><p><strong>Conclusion: </strong>The CCPP exhibited good psychometric properties suitable for clinical use, providing a valid, reliable and standardised assessment of CC's impact on HRQoL.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ERJ Open ResearchPub Date : 2025-01-13eCollection Date: 2025-01-01DOI: 10.1183/23120541.00410-2024
Jacopo Saccomanno, Lara Kilic, Thomas Sgarbossa, Konrad Neumann, Franz Stanzel, Angelique Holland, Christian Grah, Wolfgang Gesierich, Joanna Krist, Joachim H Ficker, Stephan Eggeling, Stefan Andreas, Bernd Schmidt, Stephan Eisenmann, Björn Schwick, Karl-Josef Franke, Andreas Fertl, Martin Witzenrath, Ralf-Harto Hübner
{"title":"Clinical improvements after endoscopic lung volume reduction with valves in patients with advanced emphysema and a 6-min walk test ≤140 m at baseline.","authors":"Jacopo Saccomanno, Lara Kilic, Thomas Sgarbossa, Konrad Neumann, Franz Stanzel, Angelique Holland, Christian Grah, Wolfgang Gesierich, Joanna Krist, Joachim H Ficker, Stephan Eggeling, Stefan Andreas, Bernd Schmidt, Stephan Eisenmann, Björn Schwick, Karl-Josef Franke, Andreas Fertl, Martin Witzenrath, Ralf-Harto Hübner","doi":"10.1183/23120541.00410-2024","DOIUrl":"10.1183/23120541.00410-2024","url":null,"abstract":"<p><strong>Background: </strong>Data regarding the effectiveness and safety of endoscopic lung volume reduction with valves (ELVR) in emphysema patients with a very low 6-min walk test (6MWT) are limited. Patients with severe emphysema and very low exercise capacity, as indicated by a 6MWT ≤140 m, are often excluded from clinical studies on ELVR, assuming limited therapeutic benefits and increased complication risk.</p><p><strong>Study designs and methods: </strong>This study utilised data from the Lungenemphysemregister e.V., a large German national multi-centre prospective open-label clinical trial, and aimed to assess the outcomes of ELVR in patients with a baseline 6MWT ≤140 m and dyspnoea primarily attributed to hyperinflation.</p><p><strong>Results: </strong>54 patients with a baseline 6MWT ≤140 m and 365 patients with a baseline 6MWT between 140 and 450 m were included in the study. Baseline characteristics were representative for patients with advanced lung emphysema. Patients with a 6MWT ≤140 m at baseline had a lower forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide and higher symptom burden. In the 3-month follow-up, patients of both groups showed statistically significant improvements in lung function parameters, exercise capacity and quality of life parameters compared to baseline. Patients with a 6MWT ≤140 m at baseline showed significantly more 6MWT improvement compared to patients with baseline 6MWT between 140 and 450 m. Moreover, complication rates were similar in both groups.</p><p><strong>Interpretation: </strong>In summary, the data indicate that ELVR may be an effective and safe treatment for emphysema patients with a very low 6MWT of ≤140 m if very limited exercise capacity is predominately caused by lung emphysema. Therefore future studies should include emphysema patients with a very low 6MWT.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}